Cargando…

c-MYC overexpression induces choroid plexus papillomas through a T-cell mediated inflammatory mechanism

Choroid plexus tumours (CPTs) account for 2–5% of brain tumours in children. They can spread along the neuraxis and can recur after treatment. Little is known about the molecular mechanisms underlying their formation and only few high fidelity mouse models of p53-deficient malignant CPTs are availab...

Descripción completa

Detalles Bibliográficos
Autores principales: Merve, Ashirwad, Zhang, Xinyu, Pomella, Nicola, Acquati, Serena, Hoeck, Joerg D., Dumas, Anaelle, Rosser, Gabriel, Li, Yichen, Jeyapalan, Jennie, Vicenzi, Silvia, Fan, Qianhai, Yang, Zeng Jie, Sabò, Arianna, Sheer, Denise, Behrens, Axel, Marino, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540455/
https://www.ncbi.nlm.nih.gov/pubmed/31142360
http://dx.doi.org/10.1186/s40478-019-0739-x
Descripción
Sumario:Choroid plexus tumours (CPTs) account for 2–5% of brain tumours in children. They can spread along the neuraxis and can recur after treatment. Little is known about the molecular mechanisms underlying their formation and only few high fidelity mouse models of p53-deficient malignant CPTs are available. We show here that c-MYC overexpression in the choroid plexus epithelium induces T-cell inflammation-dependent choroid plexus papillomas in a mouse model. We demonstrate that c-MYC is expressed in a substantial proportion of human choroid plexus tumours and that this subgroup of tumours is characterised by an inflammatory transcriptome and significant inflammatory infiltrates. In compound mutant mice, overexpression of c-MYC in an immunodeficient background led to a decreased incidence of CPP and reduced tumour bulk. Finally, reduced tumour size was also observed upon T-cell depletion in CPP-bearing mice. Our data raise the possibility that benign choroid plexus tumours expressing c-MYC could be amenable to medical therapy with anti-inflammatory drugs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40478-019-0739-x) contains supplementary material, which is available to authorized users.